siRNA Nanoparticle Formulation for Skin Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin cancers such as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are inadequate in effectively inhibiting TGFβ and Cox-2 gene expression, which are implicated in cancer progression, leading to limited antitumoral activity.
Innovation Solution
The use of nanoparticle formulations containing siRNAs that target TGFβ1 and Cox-2, administered via intra-tumoral injection or systemically, combined with immune checkpoint inhibitors like PD-1, PD-L1, or CTLA-4 inhibitors, to inhibit gene expression and enhance T-cell activity within the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for skin cancers, then treatment is simpler, but effectiveness in inhibiting TGFβ and Cox-2 gene expression is insufficient
Solution Approach 1:
The patent combines multiple siRNAs (targeting TGFβ1, Cox-2, and other cancer-related genes) into a single nanoparticle formulation. This merging approach delivers multiple therapeutic agents simultaneously to the tumor site, achieving effective inhibition of multiple gene expressions involved in cancer progression while maintaining a manageable treatment protocol through a unified delivery system
Solution Approach 2:
The invention uses composite nanoparticle structures that integrate multiple functional components: siRNA molecules for gene silencing, lipid or polymer materials for structural integrity and cellular uptake, and potentially targeting ligands. This composite material approach enables simultaneous delivery of multiple siRNAs with enhanced stability and targeted delivery to tumor cells
2Reliability
If nanoparticle formulations with multiple siRNAs are used, then antitumoral activity is enhanced, but formulation complexity increases
Solution Approach 1:
Multiple siRNAs targeting different cancer-related genes (TGFβ1, Cox-2, and others) are merged into a single nanoparticle formulation. This combined approach enables simultaneous silencing of multiple genes that promote tumor progression, angiogenesis, and immune suppression, thereby enhancing overall antitumoral activity through synergistic effects
Solution Approach 2:
The nanoparticle formulation is designed as a universal delivery system capable of carrying multiple types of siRNAs with different targeting sequences. This multi-functional platform can be adapted to target various cancer-related genes while maintaining a consistent delivery mechanism, reducing the need for separate formulations for each gene target
3Reliability
If siRNAs are co-delivered into the same cell, then synergistic antitumoral effect is achieved, but delivery precision requirements increase
Solution Approach 1:
The patent merges multiple siRNAs into a single nanoparticle structure, ensuring that all siRNA molecules are physically co-delivered to the same target cells. This combined delivery approach guarantees that cells receiving the nanoparticle are exposed to multiple siRNAs simultaneously, enabling synergistic gene silencing effects that enhance antitumoral activity
Solution Approach 2:
The nanoparticle formulation parameters (size, surface charge, composition) are optimized to enhance cellular uptake efficiency and ensure consistent co-delivery of multiple siRNAs. By controlling these physical and chemical parameters, the system achieves reliable simultaneous delivery of multiple therapeutic agents to target cells while maintaining manufacturability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in significant reduction of tumor growth, histological clearance of lesions, and a dose-dependent response, with enhanced T-cell penetration and reduced tumor proliferation, demonstrating a synergistic effect in treating SCC and BCC.
Implementation Method 1
RNAi agents for inhibiting TGFβ and Cox-2 gene expression are provided
Data Source
AI summary
siRNA sequences for inhibiting TGFβ and Cox-2 gene expression are provided. Methods for treatment of skin cancers, in which pharmaceutical compositions or containing these siRNA agents and complexes, are further provided, in particular, for treating squamous cell carcinoma (isSCC) and/or basal cell carcinoma (BCC). TGFβ and Cox-2 have each been implicated in driving cancer progression. TGFβ is upregulated in a number of tumor types and plays a role in stimulating cancer-associated fibroblast development. Cox-2 upregulation plays a negative role in inducing inflammation and converting active T-cells to inactive T-reg cells. Co-delivery of the two siRNAs into the same cell at the same time silences of both targets at the same time results in antitumoral activity.